All patients n = 40 | 25(OH)D >20 ng/mL n = 16 | 25(OH)D <20 ng/mL n = 24 | p-value | |
---|---|---|---|---|
Age | 40 ± 7.8 | 40.6 ± 9.2 | 41.8 ± 7.05 | 0.5 |
% Female | 35 (87%) | 13 (92.9%) | 22 (84.6%) | 0.45 |
Years of evolution | 11 ± 6.7 | 10.3 ± 7 | 12.1 ± 6.7 | 0.4 |
Number of previous relapses | 6 ± 4.2 | 4.4 ±3.4 | 7.3 ± 4.2 | 0.08 |
Annualised relapse rates | 0.35 ±0.2 | 0.4 ±0.2 | 0.3 ±0.2 | 0.2 |
EDSS | 2.5 [1–3.5] | 2.0[1.5-4.5] | 3[1–5.0] | 0.02 |
Oligoclonal bands | 23 (54%) | 9 (56.2%) | 14 (58.3%) | 0.28 |
HLADR15 positive | 8 (21%) | 4 (28.6%) | 4 (15.4%) | 0.3 |
Proliferation of T cells to myelin peptides | 28 (70%) | 5 (35.7%) | 23 (88.5%) | 0.001* |
Number of lesions in T2 | 42.5 ± 36 | 30.7 ± 23.7 | 44 ± 38 | 0.4 |
Number of contrast- enhancing lesions | 0.85 ± 2 | 0.4 ± 0.9 | 1.2 ± 2.6 | 0.8 |